Other Clients/Companies To Watch:
Access Pharmaceuticals,
Inc
(OTC: ACCP)
Alexza
Pharmaceuticals, Inc.
(NASDAQ:ALXA)
Crucell
N.V.
(Euronext, NASDAQ: CRXL)
DelSite
Biotechnologies, Inc.
(OTC: DSII)
Digital
Angel Corporation
(AMEX:DOC)
Duska Therapeutics,
Inc.
(OTC:DSKA)
KERYX Biopharmaceuticals,
Inc.
(NASDAQ:KERX)
Manhattan Pharmaceuticals,
Inc.
(AMEX:MHA)
Mediware Information Systems, Inc. (NASDAQ: MEDW)
Pipex Pharmaceuticals,
Inc.
(OTC:PPXP.OB)
Redpoint Bio Corporation
(OTC:RPBC)
|
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates.
|